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Introduction
Zinc-alpha2-glycoprotein (AZGP1) is a 40-kDa protein located on human chromosome 7q22.1, and is secreted in various body fluids. AZGP1 is expressed mainly in epithelial cells of the breast, the prostate, the liver and various gastrointestinal organs (1) . AZGP1 has been associated with cancer cachexia due to its high amino acid sequence homology with tumor-derived lipidmobilizing factor (2) . In a mouse AZGP1-producing tumor model, AZGP1 stimulated lipolysis in adipocytes, leading to cachexia (3) .
In addition to the role of AZGP1 in lipid metabolism, AZGP1 has been reported to be involved in the progression and prognosis of many tumors (4) (5) (6) . AZGP1 is a potential biomarker for different types of carcinomas (7) (8) (9) (10) . Previous research has shown that AZGP1 inhibits the proliferation of the human cervical tumor cell SiHa and the colorectal cancer cell line LoVo by inducing G2/M phase arrest (11, 12) . Furthermore, AZGP1 inhibits the invasion of pancreatic cancer cells and hepatocellular carcinoma (HCC) cells by blocking TGF-β-mediated epithelialmesenchymal transition (EMT) (13, 14) . Although previously reported that low expression of AZGP1 was associated with poor overall survival of HCC patients, the molecular mechanism of regulation of AZGP1 in HCC remains unclear (15) . For this reason, it is important to elucidate the mechanisms of regulation of AZGP1 in HCC.
In this study, we explored the regulatory mechanism of expression of AZGP1 in HCC and its clinical significance. The role of AZGP1 in HCC progression and its underlying molecular mechanisms was also investigated.
Materials and methods

Cell lines and cell culture
Huh7 cells were obtained from Riken Cell Bank (Tsukuba, Japan). HepG2 cells were obtained from American Type Culture Collection (ATCC). SMMC-7721 cells were obtained from the cell bank of the Institute of Biochemistry and Cell Biology of the Chinese Academy of Sciences (Shanghai, China). MHCC-97L and HCC-LM3 cells were provided by the Liver Cancer Institute of Zhongshan Hospital of Fudan University (Shanghai, China). SMMC-7721, MHCC-97L, HepG2 and Huh7 were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum at 37°C in 5% CO 2 . All cell lines were authenticated and characterized by the supplier. The cells were expanded immediately or cryopreserved. Cells were used within 6 months of resuscitation.
Vector constructs
To generate stable AZGP1-overexpressing cell lines, the AZGP1 ORF (open reading frame) sequence was PCR amplified using specific primers (forward: 5′-ATGGTAAGAATGGTGCCTGT -3′, and reverse: 5′-CTAGCTG GCCTCCCAGGGC-3′) and cloned into the lentiviral expression vector pWPXL (Addgene). To generate stable knockdown cell lines, Akt and CD44s shorthairpin RNA (shRNA) vectors were constructed. Three target sequences of AZGP1 were selected: AZGP1-1: 5′-CCAGGGAGGACAUCUUUAUTT-3′ AZGP1-2: 5′-GCGGAGCAUUCUGGAAAUA -3′; AZGP1-3: 5′-GGGAGAUGUUCUUCACAAU -3′. Two target sequences of Akt were selected: 5′-CGAGGGGAGTACATCAAGA -3′; and 5′-AGATGACAGCATGGAGTGT-3′.
Two target sequences of CD44s were selected: 5′-CCGCTTTGCA GGTGTATTC -3′; and 5′-AAATGGTCGCTACAGCATC-3′. A shRNA with a non-targeting sequence (scrambled sequence) was used as a negative control (shNC) in our experiment. The sequences of scrambled were TTCTCCGAACGTGTCACGTT. These sequences were synthesized and inserted into the pLVTHM vector (Addgene) in accordance with the manufacturer's instructions. The AZGP1 promoter were generated by PCR and cloned into the luciferase reporter gene vector, pGL3-enhancer (Promega, Madison, WI). The fidelities of the constructs were confirmed by sequencing. The primer information is listed in Supplementary Table 1, available at Carcinogenesis Online.
Luciferase assay
Cells were cotransfected with the corresponding reporter plasmid and the indicated plasmids in each experiment according to the standard protocol. The pRL-TK reporter construct was used as an internal control. Luciferase activity was detected using the Dual-Luciferase Report Assay (Promega) system in accordance with the manufacturer's instructions.
Lentivirus production and cell transduction
Viral packaging was performed in HEK 293T cells after co-transfection of the pWPXL-AZGP1 vector or the pLVTHM-shAZGP1 vector with the packaging plasmid psPAX2 and the envelope plasmid pMD2.G (Addgene) using Lipofectamine 2000 (Invitrogen).Viruses were harvested 72 h after transfection, and viral titers were determined. Target cells, including Huh7, SMMC-7721, MHCC-97L and HepG2 cells, were infected with 1 × 10 6 recombinant lentivirus-transducing units in the presence of 6 μg/ml polybrene (Sigma).
Western blotting
Western blotting was performed following the protocol described (8) . Antibody information is listed in Supplementary Table 2 , available at Carcinogenesis Online.
Quantitative real-time RT-PCR (qRT-PCR)
Total RNA was extracted using Trizol (Invitrogen, CA), and the RNA samples were reverse transcribed into cDNA using a PrimeScript RT reagent kit (Takara, Dalian, China). qRT-PCR was performed using an ABI Prism 7500 System (Applied Biosystems, Carlsbad, CA) with the SYBR ® Premix Ex Taq (Takara, Dalian, China). The primer information is listed in Supplementary 
RNA interference
We designed a shRNA construct to target AZGP1, Akt, CD44s and Ikaros. Sequence information is listed in Supplementary Table 3, available at Carcinogenesis Online.
Chromatin immunoprecipitation assay (ChIP)
Chromatin immunoprecipitation assay assays were performed using a ChIP assay kit according to the manufacturer's instructions (Upstate Biotechnology). Rabbit anti-acetyl-histone H3 (Lys 9,18), rabbit anti-acetylHistone H4 (Lys 5, 8, 12 and 16), rabbit anti-Ikaros or rabbit IgG were used to immunoprecipitate DNA-containing complexes. DNA from these samples was subjected to PCR analyses with primer sets for AZGP1. The primer information is listed in Supplementary Table 1, available at Carcinogenesis Online.
Immunohistochemistry
A tissue microarray containing 236 HCC tissues was used for immunohistochemical procedures. Immunohistochemistry, signal evaluation, and statistical data analysis were performed as previously described (16) . Antibody information is listed in Supplementary Table 2, available at Carcinogenesis Online. All samples were obtained with approval from the Institutional Ethics Committee.
Immunofluorescent confocal imaging
Cells were seeded onto glass slides for 24 h, fixed in 4% paraformaldehyde and permeabilized with 0.5% Triton X-100 for 15 min. The slides were then incubated with primary antibody in blocking solution overnight at 4°C in a humidified chamber. The glass slides were then washed three times in phosphate-buffered saline and incubated in Alexa 594-conjugated secondary antibody and 4′6-diamino-2-phenylindole (DAPI) in blocking solution for 60 min at 37°C in a humidified chamber. Images were obtained with a confocal laser microscope (IX-70, Olympus 60M, Olympus, London, UK).
Enzyme-linked immunosorbent assay (ELISA)
One hundred twenty-five HCC serum specimens were obtained from patients who underwent surgical treatment at Guangxi Cancer Institute (Nanning, China) and Qidong Liver Cancer Institute (Qidong, China) 
In vitro migration and invasion assays
For the in vitro migration and invasion assays, cells were seeded on the upper chamber of a transwell or on a matrigel-coated transwell (BD Biosciences, NJ) in serum-free media. The lower chamber contained DMEM with 10% fetal bovine serum as a chemoattractant. After 24 or 48 h of incubation, the non-migrated or non-invaded cells were gently removed from the upper chamber using a cotton swab. The cells were fixed and stained using Giemsa solution and counted in five randomly chosen visual fields.
In vivo growth and metastasis assays
For the in vivo growth and metastasis assay, 2 × 10 6 cells were suspended in 40 μl of a mixture of serum-free DMEM/Matrigel (1:1 volume) (BD Biosciences, MA) for each male nude mouse. For the in vivo growth assay, the nude mice were subcutaneously injected in the flank with AZGP1-overexpressing cells or control cells. For the in vivo growth assay, each nude mouse was orthotopically inoculated in the left hepatic lobe with a microsyringe through an 8-mm transverse incision in the upper abdomen under anesthesia. For the in vivo metastasis assay, 3 × 10 6 cells were injected into the lateral tail veins of a nude mouse. Nine weeks later, the mice were sacrificed, and the tumors and individual liver and lung tissues were excised and fixed with 4% phosphate-buffered neutral formalin for at least 72 h. Metastatic tissues were analyzed by H&E staining. All of the experiments were approved by Shanghai Medical Experimental Animal Care Commission.
Statistical analyses
Statistical analyses were performed using the SPSS16.0 software. All data are shown as the mean ± SD. Statistical analysis was performed using the Chi-square test. Two-group comparisons were performed using a t-test. Log-rank tests were used to compare patient survival between subgroups. Multivariate analyses were performed using the Cox multivariate proportional hazard regression model in a stepwise manner (forward, likelihood ratio); P < 0.05 was considered significant.
Results
Ikaros binds to the AZGP1 promoters and promotes their expression in HCC cells
Although downregulation of AZGP1 in HCC has been reported in previous study, the molecular mechanism of regulation of AZGP1 in HCC remains unclear (14) . To assess the regulatory mechanism of AZGP1 in HCC, we performed a reporter assay to identify regulatory elements that control AZGP1 transcription. The use of deletion constructs showed that luciferase activity was decreased in the -200/-5-bp construct compared with the -1123/-5-bp, -423/-5-bp and -358/-5-bp constructs ( Figure 1A ). These results suggested that at least one regulatory element is located between nucleotides −358 and −220. Bioinformatics analysis predicted putative regulatory elements such as HSF, GATA2, Egr-1, Foxd3, GATA3, NF-кB, MZF1, USF1 and Ikaros between nucleotides −358 and −220. The results showed that HSF, GATA2, NF-кB, Egr-1, Foxd3, GATA3, USF1 and MZF1 did not regulate AZGP1 promoter activity, according to the luciferase assay ( Figure 1B and C). However, a conserved Ikaros binding motif was found at position −254 to −242 bp, indicating that Ikaros could be implicated in the regulation of AZGP1 transcription. Luciferase assays revealed that Ikaros increased AZGP1 promoter activity in a dose-dependent manner ( Figure 1D and E). However, Ikaros did not increase the activity of AZGP1 promoter containing a putative Ikaros-mutated binding site ( Figure 1E ). The binding of Ikaros to AZGP1 promoters was further confirmed by ChIP assay ( Figure 1F ). Moreover, Ikaros overexpression increased the AZGP1 expression level in HCC cells ( Figure 2A ). In contrast, AZGP1 mRNA expression was downregulated in Ikarosknockdown HCC cells ( Figure 2B ). The above results showed that Ikaros binds to the AZGP1 promoter and promotes its expression in HCC cells. To further explore potential clinical applications of the experimental data, we next detected the expression of AZGP1 and Ikaros in human primary HCC tissues by qRT-PCR and immunohistochemistry. Our results showed that there was a significant positively correlated with expression of AZGP1 and Ikaros in HCC tissue ( Figure 2C-E) .
Low AZGP1 expression can be regulated by histone deacetylase in HCC
Epigenetic aberrations can lead to the silencing of tumor suppressor genes both independently and in conjunction with deleterious genetic mutations or deletions. To assess the mechanism underlying the downregulation of AZGP1 in HCC, we performed demethylation and deacetylation-inhibition assays. Our results showed that demethylation using 5-Aza-2′-deoxycytidine (5-Aza-dC) did not upregualte AZGP1 expression in HCC cells (Supplementary Figure 1 , available at Carcinogenesis Online). However, histone deacetylase (HDAC) inhibitor Trichostatin A (TSA) significantly upregulated AZGP1 expression and protein secretion in the HCC cells and supernatant ( Figure 3A and B) . Therefore, these results suggest that histone acetylase modifications are involved in the regulation of AZGP1 expression in HCC.
Histone H3 and H4 acetyltransferase plays a particularly important role in histone acetylase modifications. Therefore, we examine the expression of acetylation of histone H4 and HDAC1 expression in the TSA-treated HCC cells. The results showed that TSA reconstituted acetylation of histone H4 expression; meanwhile, HDAC1 expression was downregulated in HCC cells ( Figure 3C ). Furthermore, immunofluorescence assay results showed that TSA promoted AZGP1 and the acetylation of histone H4 expression in HCC cells. The immunofluorescence of AZGP1 and acetylation of histone H4 double-labeling also showed colocalization in both nucleoli and nucleoplasmic foci in HCC cells ( Figure 3D ).In addition, a ChIP assay revealed a significantly increased binding of acetylated histone H4 to the AZGP1 promoter in TSA-treated cells ( Figure 3E and Supplementary 2A, available at Carcinogenesis Online), indicating an open chromatin conformation within that region. However, TSA did not increase the binding of acetylated histone H3 to the AZGP1 promoter (Supplementary Figure 2B , available at Carcinogenesis Online).
To explore whether histone acetylation regulates AZGP1 expression via transcription factor Ikaros, we analyzed the expression of Ikaros in HCC cells treated with TSA. Our results showed that TSA increased Ikaros protein and mRNA expression ( Figure 3F and Supplementary Figure 3 , available at Carcinogenesis Online). Therefore, we speculated that acetylation of histone H4 might increase AZGP1 expression by transcription factor Ikaros binding to the promoter of AZGP1 in HCC cells. In addition, we also analyzed the effects of Ikaros on the expression of HDAC1 and acetylation of histone H4 in HCC cells. Our results showed that exogenous expression of AZGP1 inhibited expression of HDAC1, meanwhile, acetylation of histone H4 expression was upregulated in HCC cells ( Figure 3G ). Conversely, AZGP1 knockdown promoted expression of HDAC1, meanwhile, acetylation of histone H4 expression was inhibited in HCC cells ( Figure 3H ). Therefore, we postulated that a positive feedback loop may exist between the Ikaros and histone acetylation in HCC.
Down-regulated AZGP1 expression predicts poor prognosis in HCC patients
Previous study showed that expression of AZGP1 was downregulated and related with prognosis of patients in HCC. Our results also showed that of the 236 pairs, 186 (78.8%) had lower AZGP1 protein expression in the tumor liver tissues than in the non-tumor tissues, 47 (19.9%) had similar expression and only 3 (1.3%) had higher expression ( Figure 4A ). Moreover, protein and mRNA levels of AZGP1 were also downregulated in HCC tissues compared with non-cancerous tissues according to Western blot and qPCR results ( Figure 4B and C) . These results indicated that AZGP1 expression was downregulated in HCC. In addition, we found that expression AZGP1 was downregulated in HCC tissues with metastasis compared to those without metastasis according to Western blot and qRT-PCR results (Supplementary  Figure 4 , available at Carcinogenesis Online).
Although AZGP1 is a secreted glycoprotein, there was no report about serum level of AZGP1 in HCC. We next detected and compared the serum AZGP1 protein levels in 72 healthy individuals and 125 HCC patients. Serum AZGP1 levels were significantly lower in HCC patients (8.87 ± 9.56 μg/ml) than in the normal controls (20.29 ± 10.51 μg/ml) (P < 0.01) ( Figure 4D) . Thus, serum level of AZGP1 was frequently downregulated in HCC patients.
To determine the relationship between serum AZGP1 levels and clinicopathological parameters, a cutoff value of 7.01 μg/ml was determined with a sensitivity of 88.9% and a specificity of 52% by receiver operating characteristic analysis (Supplementary Figure 4 , available at Carcinogenesis Online). Using the 7.01 μg/ml threshold for AZGP1, we found that the serum AZGP1 level was negatively correlated with the HBV infection (Supplementary  Tables 5 and 6 , available at Carcinogenesis Online). However, the Table 5 , available at Carcinogenesis Online). Kaplan-Meier analysis showed that patients in the high AZGP1 expression group had longer overall survival than the lowexpression group (log-rank, P = 0.040, Figure 4E ). In addition, we found that patients with downregulated AZGP1 and upregulated AFP expression displayed a worse prognosis than those patients with downregulated AZGP1 or upregulated AFP expression (Supplementary Figure 6 , available at Carcinogenesis Online). Furthermore, multivariate COX proportional hazard analysis suggested that high serum AZGP1 level was associated with better survival of HCC patients (HR = 0.453, 95% CI = 0.206-0.994, P = 0.048; Figure 4F ). Thus, these findings suggested that AZGP1 could serve as a valuable predictive factor for HCC patients.
AZGP1 inhibits HCC cell growth, migration, invasion and metastasis in vitro and in vivo
To elucidate the effects of AZGP1 on hepatoma cell behavior, SMMC-7721, MHCC-97L and Huh7 cells, which have low expression levels of endogenous AZGP1, were infected with lentiviral-AZGP1 (Supplementary Figure 7 , available at Carcinogenesis Online). Our results showed that the exogenous expression of AZGP1 dramatically inhibited cell growth and clone formation (Supplementary Figure 8A Figure 8D and E, available at Carcinogenesis Online).
We next detected the role of AZGP1 in HCC cell migration and invasion. Migration and Matrigel invasion assays showed that the exogenous expression of AZGP1 dramatically decreased cell mobility compared with lentiviral-infected control cells ( Figure 5A ). Similarly, cell migration and invasion were significantly inhibited by recombinant AZGP1 protein ( Figure 5B ). In contrast, AZGP1 knockdown increased HCC cell migration and invasion ( Figure 5C ).
To further clarify the role of AZGP1 in HCC migration and invasion in vivo, AZGP1-overexpressing HCC cells were injected into the lateral tail veins of nude mice. The results showed that the number of lung metastasis nodules was significantly decreased in the AZGP1-overexpressing group compared with the control group ( Figure 5D, Supplementary Figure 10 , available at Carcinogenesis Online). Taken together, these findings suggest that AZGP1 suppresses HCC migration and invasion.
AZGP1 inhibits HCC cell migration and invasion through the PTEN/Akt and CD44s pathways
Our previous study showed that RRM2B inhibits cell metastasis through the PTEN/Akt pathway (16) . Therefore, we investigated the role of the PTEN/Akt pathway in the AZGP1-induced Figure 6A ). PTEN negatively regulates the PI3K/ Akt pathway (17) . Therefore, we also investigated Akt phosphorylation in AZGP1-overexpressing and AZGP1-knockdown HCC cells. The results showed that AZGP1 overexpression inhibited Akt phosphorylation in HCC cells. Moreover, the same effects were found in recombinant human AZGP1-treated HCC cells and murine xenografts from AZGP1-overexpressing HCC cells ( Figure 6B ). In contrast, AZGP1 knockdown resulted in increased levels of phosphorylated Akt in HCC cells ( Figure 6C ).
CD44s plays an important role in inducing EMT in HCC (18) . Therefore, we detected the effect of AZGP1 on the expression of CD44s in HCC cells. The results showed that AZGP1 overexpression suppressed CD44s in HCC cells ( Figure 6A ). Moreover, the same effects were observed in recombinant human AZGP1-treated HCC cells ( Figure 6B ). In contrast, AZGP1 knockdown promoted CD44s expression in HCC cells ( Figure 6C ). The same effects were also found in murine xenografts from AZGP1-overexpressing HCC cells ( Figure 6D) .
To confirm the role of Akt and CD44s in AZGP1-inhibited HCC migration and invasion, we constructed Akt and CD44s shRNA to knockdown Akt and CD44s expression in AZGP1 knockdown HCC-LM3 cells. Our results showed that AZGP1 overexpressioninduced suppression of cell migration and invasion can be partially reversed by the overexpression of CD44s ( Figure 6E , Supplementary Figure 11 , available at Carcinogenesis Online). In contrast, AZGP1 knockdown-induced cell migration and invasion can be partially reversed by the knockdown of CD44s ( Figure 6F, Supplementary Figure 11 , available at Carcinogenesis Online). In addition, AZGP1 overexpression-induced suppression of cell migration and invasion can be partially reversed by the overexpression of Akt. In contrast, AZGP1 knockdown-induced cell migration and invasion can be partially reversed by the knockdown of Akt ( Figure 6G and H, Supplementary Figure 12 , available at Carcinogenesis Online). Therefore, these data suggest that both PTEN/Akt and CD44s signaling are required in AZGP1-inhibited HCC migration and invasion.
To further explore potential clinical applications of the experimental data, we next detected the expression of AZGP1, PTEN, p-Akt, Akt and CD44s in human primary HCC tissues by Western blot. Results showed that a correlation between AZGP1 levels and the expression of PTEN, p-Akt1and CD44s was observed in human HCC tissues (Supplementary Figure 13A , available at Carcinogenesis Online). Furthermore, AZGP1 expression negatively correlated with CD44s expression in HCC tissues and The Cancer Genome Atlas (TCGA) cohort (Supplementary Figure 13B and C, available at Carcinogenesis Online). Therefore, these data suggest that both PTEN/Akt and CD44s signaling are required in AZGP1-inhibited HCC metastasis.
Discussion
HCC is the most common malignant tumor worldwild and is particularly prevalent in China, Southeast Asia and Western countries (19) . HCC patient prognosis remains poor, mainly due to its propensity for metastatic progression and poor response to pharmacological treatment (20) . Therefore, the identification of metastatic factors and elucidation of the underlying molecular mechanism that are involved in the progression of metastasis have become critical issues. In this study, we demonstrated that the transcription factor Ikaros and histone deacetylation regulated AZGP1 expression in HCC. Downregulated AZGP1 in HCC serum samples was associated with prognosis of patients. Furthermore, AZGP1 inhibited cell migration and invasion via the modulation of the PTEN/Akt and CD44s pathway in HCC.
Although abnormal AZGP1 expression is found in many human tumors, such as breast cancer, prostate cancer, pancreatic cancer, gastric cancer and HCC, suggesting that it might be a possible prognosis marker for tumor patients, little is known regarding the regulatory mechanism of AZGP1 in HCC (7, 9, 10, 13, 14) . In this study, we found one possible explanation for the low expression of AZGP1 in HCC. Epigenetic dysregulation is among the most common abnormalities observed in human cancers. DNA methylation and histone modification are known to have profound effects on chromosome stability and gene transcription (21) . In this study, the treatment of HCC cells with HDAC inhibitors increases the levels of acetylated histone H4 at the AZGP1 promoter and correspondingly increases the expression of AZGP1. However, the treatment of HCC cells with inhibitors of DNA methylation does not increase the levels of AZGP1. Therefore, histone acetylation rather than DNA methylation was found to play an important role in regulating AZGP1 expression in HCC. Furthermore, a previous study showed that HDACs are upregulated in HCC samples (22) . This result indicated that loss-of-expression AZGP1 is partly associated with histone deacetylation in HCC. Second, we found that the transcription factor Ikaros can direct bind to AZGP1 promoter and increase AZGP1 expression in HCC. Ikaros is a member of the Kruppel family of zinc finger DNA-binding protein, which is the crucial regulator of normal hematopoiesis, and has been identified as a tumor suppressor associated with the development of leukemia (23, 24) . Our previous report showed that Ikaros is downregulated and associated with poor survival in HCC patients (25) . Therefore, we speculated that the decreased expression of Ikaros in HCC is one of the reasons leading to the decreased expression AZGP1. Interestingly, we found that acetylation of histone H4 increases AZGP1 expression by transcription factor Ikaros binding to the promoter of AZGP1 in HCC cells. Furthermore, Ikaros inhibits the expression of HDAC1, meanwhile, acetylation of histone H4 is upregulated in HCC cells. Therefore, we postulated that a positive feedback loop exists between the Ikaros and histone acetylation in HCC. This positive loop may regulate AZGP1 expression in HCC.
To date, multiple oncogenic pathways have been reported to participate in metastasis regulation, such as MAPKs, PI3K/ Akt, CD44s, and so forth. In this study, we identified PTEN/ Akt and CD44s as critical downstream signaling effectors of AZGP1. Increasing evidence has demonstrated that the activated PI3K/Akt and CD44s pathways play a central role in the EMT process and correlate with an aggressive phenotype in several types of malignancies (26) (27) (28) . Our results showed that AZGP1 inhibits cell migration and invasion through PTEN/Akt-and CD44s-dependent mechanisms. Furthermore, previous work has shown that the CD44s and Akt pathways are aberrantly activated in HCC (29, 30) . CD44 knockdown inhibits HCC invasion and metastasis by reversing EMT (28) . In addition, high CD44s expression is a poor prognostic factor following curative hepatic resection of primary HCC (18) . Therefore, these results illustrate that the low expression of AZGP1 can activate the PTEN/Akt and CD44s pathway in HCC, affecting HCC patient prognosis. However, the mechanisms of regulating PTEN/Akt and CD44s expression by AZGP1 in HCC are not clear. PTEN is positively and negatively regulated at the transcriptional level, as well as post-translationally by phosphorylation, ubiquitylation, oxidation and acetylation. Transcription factors p53, snail, slug and early growth regulated transcription factor 1 (EGR1) regulate PTEN transcription (16, (31) (32) (33) (34) . Our results showed that AZGP1 inhibits snail and slug expression in HCC cells (Supplementary Figure 14 , available at Carcinogenesis Online). Therefore, we speculated that AZGP1 might increase PTEN expression through regulating snail and slug in HCC. Expression of CD44s is regulated by many extracellular or intracellular factors during tumor development (35) . Transforming growth factor β (TGF-β) is a multifunctional factor and is known to affect tumor growth in malignant tumors (36) . Previous study showed that TGF-β upregulates CD44s expression in prostate cancer cells (37) . Our results also showed that overexpression of AZGP1 inhibits TGF-β-induced the expression of EMT markers and cell migration and invasion in HCC cells (Supplementary Figure 15 , available at Carcinogenesis Online). Furthermore, previous study also showed that AZGP1 suppresses EMT and hepatic carcinogenesis by blocking TGFβ1-ERK2 pathways (15) . Thus, these results implied that AZGP1 might inhibit CD44s expression, at least partially, via the regulation of TGF-β in HCC.
In conclusion, our study demonstrates that the reduced expression of AZGP1 in HCC is a strong indicator of more aggressive tumors and poor clinical outcome. AZGP1 suppresses PTEN/
